Shares of GlaxoSmithKline plc (LON:GSK – Get Rating) have been given an average rating of “Hold” by the fourteen research firms that are currently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is GBX 1,705.38 ($22.19).
GSK has been the subject of a number of research reports. Barclays reaffirmed an “equal weight” rating and issued a GBX 1,675 ($21.79) target price on shares of GlaxoSmithKline in a report on Monday, April 11th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,700 ($22.12) target price on shares of GlaxoSmithKline in a report on Wednesday, March 30th. Jefferies Financial Group set a GBX 2,100 ($27.32) price target on shares of GlaxoSmithKline in a report on Tuesday. UBS Group set a GBX 1,790 ($23.29) price target on shares of GlaxoSmithKline in a report on Monday, April 11th. Finally, Credit Suisse Group set a GBX 1,400 ($18.21) price target on shares of GlaxoSmithKline in a report on Thursday, February 10th.
LON GSK opened at GBX 1,759.60 ($22.89) on Wednesday. The company has a debt-to-equity ratio of 113.27, a current ratio of 0.79 and a quick ratio of 0.53. GlaxoSmithKline has a 1 year low of GBX 1,313.40 ($17.09) and a 1 year high of GBX 1,801.60 ($23.44). The company has a market capitalization of £89.46 billion and a PE ratio of 20.32. The company has a fifty day moving average of GBX 1,622.22 and a two-hundred day moving average of GBX 1,579.67.
In other GlaxoSmithKline news, insider Charles Bancroft purchased 2,790 shares of the stock in a transaction dated Wednesday, March 23rd. The shares were acquired at an average cost of GBX 2,114 ($27.50) per share, for a total transaction of £58,980.60 ($76,737.70). Also, insider Emma Walmsley sold 34,031 shares of the stock in a transaction that occurred on Monday, February 14th. The shares were sold at an average price of GBX 1,610 ($20.95), for a total transaction of £547,899.10 ($712,853.37).
GlaxoSmithKline Company Profile (Get Rating)
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.